Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Brochure More information from http://www.researchandmarkets.com/reports/1801555/ Sanofi-Aventis Acquires Genzyme Corporation for $20 billion Description: Sanofi-Aventis Acquires Genzyme Corporation for $20 billion - Deal Analysis from GlobalData Summary Following acquisition by Sanofi-Aventis for about $20 billion, Genzyme Corporation will become a new platform in Sanofi-Aventis’s sustainable growth strategy and expand the company's presence in biotechnology targeting rare diseases, renal-endocrinology, hematology-oncology, and the biosurgery segment. Genzyme will continue to operate out of its current headquarters in Massachusetts, and will be headed by Sanofi-Aventis CEO Christopher Viehbacher. Genzyme had earlier rejected several offers from Sanofi-Aventis last year, which included a deal worth $18.5 billion, or $69 per share. The two companies ultimately settled on a price of $74 per share. Scope - On April 8, 2011, Sanofi-aventis completed the acquisition of Genzyme for about $20 billion in total, or $74 per share plus extra payments of up to $14 per share. The extra payments would depend on the achievement of commercial milestones of the leukemia drug Campath (alemtuzumab) in the multiple sclerosis (MS) therapy area, where it will be sold as Lemtrada, for which Genzyme executives estimated sales to reach $3.5 billion. They are also based on the production levels of Genzyme products Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta), which had commercial setbacks following manufacturing issues in 2009. Reasons to buy - Several top selling products from Sanofi-Aventis such as Aprove, Lovenox, Multaq, Taxotere, and Plavix face competition from generic versions, and this acquisition can ensure considerable expansion into rare diseases, renal-endocrinology, hematology-oncology and the biosurgery segment. - Genzyme's clinical research is focused on the areas of medicine where it markets commercial products, namely rare inherited diseases, renal disease, orthopedics, oncology, transplantation, and immune diseases. It also conducts research in cardiovascular disease, neurodegenerative diseases, and other areas with unmet medical needs. The company has product candidates across various stages of development, from pre -clinical studies to post-marketing studies. Contents: 1 1 1.1 List of Tables 2 Summary 3 Deal Overview 4 Deal Rationale 5 Financials 6 Deal History 7 Companies Overview 7.1 Sanofi-Aventis 7.1.1 Overview 7.1.2 Chief Executive Officer (CEO) 7.1.3 Revenue (2010) 7.1.4 R&D Spend (2010) 7.1.5 Employee Strength 7.1.6 Geographic Presence 7.2 Genzyme 7.2.1 Overview 7.2.2 Chief Executive Officer (CEO) 7.2.3 Revenue (2010) 7.2.4 R&D Spend (2010) 7.2.5 Employee strength 7.2.6 Geographic Presence 8 Appendix 8.1 Methodology 8.1.1 Coverage 8.1.2 Secondary Research 8.1.3 Primary Research 8.1.4 Expert Panel Validation 8.2 Contact Us 8.3 Disclaimer 1.1 List of Tables Table 1: Genzyme Late Stage Drug Development Portfolio Table 2: Comparison of Therapy Areas under Drug Development and Research Ordering: Order Online - http://www.researchandmarkets.com/reports/1801555/ Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland. Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/ Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Sanofi-Aventis Acquires Genzyme Corporation for $20 billion Web Address: http://www.researchandmarkets.com/reports/1801555/ Office Code: SCHL3FA7 Product Formats Please select the product formats and quantity you require: Quantity Electronic (PDF) Single User: USD 500 Electronic (PDF) Site License: USD 1000 Electronic (PDF) Enterprisewide: USD 1500 Contact Information Please enter all the information below in BLOCK CAPITALS Title: First Name: Mr Mrs Dr Miss Last Name: Email Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL) Ms Prof Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number 833 130 83 Sort code 98-53-30 Swift code ULSBIE2D IBAN number IE78ULSB98533083313083 Bank Address Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646) 607-1907 or (646) 964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World